What are the key pathological features of Alzheimer's disease?
The accumulation of beta amyloid plaques and neurofibrillary tangles, leading to neurodegeneration and synaptic loss.
2
New cards
Describe the role of cholinergic neurons in Alzheimer's disease.
Cholinergic neurons in the basal forebrain are essential for memory and cognitive function, and their degeneration correlates with the severity of cognitive impairment.
3
New cards
What types of drugs are commonly used to treat Alzheimer's disease?
Acetylcholinesterase inhibitors and NMDA glutamate receptor antagonists.
4
New cards
How do acetylcholinesterase inhibitors work?
They prevent the breakdown of acetylcholine, increasing its levels in the brain to enhance cholinergic transmission.
5
New cards
What is the mechanism of action of NMDA receptor antagonists?
They block NMDA receptors to reduce excitotoxicity caused by excessive glutamate.
6
New cards
What is the blood-brain barrier and its significance in treating Alzheimer's disease?
The blood-brain barrier is a selective permeability barrier that restricts harmful substances from entering the brain, making drug delivery a challenge.
7
New cards
What is the beta amyloid hypothesis in Alzheimer's disease?
The hypothesis that the accumulation of beta amyloid plaques drives neurodegeneration and cognitive decline.
8
New cards
What genetic factors are associated with early-onset Alzheimer's disease?
Mutations in the amyloid precursor protein (APP) gene and presenilins-1 and -2, which lead to abnormal amyloid beta production.
9
New cards
What is meant by disease-modifying therapies in Alzheimer's treatment?
Therapies that aim to target the underlying pathophysiology of Alzheimer's disease rather than just managing symptoms.
10
New cards
What are some emerging treatments in development for Alzheimer's disease?
Monoclonal antibodies targeting amyloid plaques, tau-targeted therapies, and anti-inflammatory drugs.
11
New cards
What are the common side effects of acetylcholinesterase inhibitors?
Nausea, vomiting, diarrhea, insomnia, and muscle cramps.
12
New cards
How is cognitive impairment related to acetylcholine levels in Alzheimer's disease?
Decreased acetylcholine levels from cholinergic neuron loss lead to impairments in memory and learning.
13
New cards
What is the role of tau protein in Alzheimer's disease?
Hyperphosphorylated tau forms neurofibrillary tangles that disrupt neuronal transport and contribute to cell death.
14
New cards
What lifestyle factors can influence the progression of Alzheimer's disease?
Cardiovascular health, diet, physical activity, and cognitive engagement.
15
New cards
Why is early detection and symptom management critical in Alzheimer's disease?
Because there is currently no cure, managing symptoms and providing support can improve the quality of life.
16
New cards
What do PET scans reveal about the brains of Alzheimer's patients?
Reduced energy metabolism and brain activity, indicating neuronal dysfunction.
17
New cards
How do recent advancements in monoclonal antibody therapies aim to treat Alzheimer's disease?
By promoting clearance of amyloid plaques and reducing neuronal degeneration.
18
New cards
What challenges exist in developing effective therapies for Alzheimer's disease?
Concerns about efficacy, safety, and adverse effects like amyloid-related imaging abnormalities.
19
New cards
How is Alzheimer's disease classified based on onset?
Into early-onset (rare, genetically driven) and late-onset (common, with complex interactions of factors).
20
New cards
What is meant by 'excitotoxicity' in the context of Alzheimer's disease?
Excessive glutamate activity that causes neuronal damage and cell death.
21
New cards
How does the cholinergic hypothesis relate to Alzheimer's treatment?
It drives the use of cholinergic enhancement therapies to compensate for neuronal loss.
22
New cards
What is Alzheimer's disease characterized by?
A gradual decline in cognitive function, particularly in memory, language, and daily activities.
23
New cards
What are some research directions for future therapies in Alzheimer's disease?
Combination therapies targeting multiple disease pathways, including amyloid reduction and anti-inflammatory strategies.